The CNS disease drug developer has raised funding in a GV-backed round just four months after it emerged from UT Southwestern with $30m.

Osage University Partners backed a round for Aerovate Therapeutics that will go to testing an inhaled version of the latter's pulmonary disease therapy.

Gene therapy developer Freeline Therapeutics priced an upsized offering at the top of its range following $275m in funding from investors including Novo.

Koch Industries and CK Hutchison both participated in a series D round that pushed the medical imaging system developer's total funding to more than $124m.

The CNS disease drug developer has raised funding in a GV-backed round just four months after it emerged from stealth with $30m.

The mental healthcare app developer boosted its overall funding to $120m in a round that included Cigna Ventures and Kaiser Permanente Ventures.

Cigna and Kaiser Permanente have participated in a $50m series D round for Ginger, bringing the MIT spinout's total funding to more than $120m.

UCL's Freeline Therapeutics has priced its shares at $18 to raise nearly $159m through an IPO on the Nasdaq Global Select Market.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.

Humana-backed primary care network Oak Street Health is raising $328m in an offering in which it priced its shares above an expanded range.